20:58 , Apr 6, 2018 |  BC Week In Review  |  Clinical News

Oxford BioDynamics reports data for predicting inadequate responders to methotrexate

Oxford BioDynamics plc (LSE:OBD) and colleagues reported that the presence of a five-marker Chromosome Confirmation Signature (CCS) in the blood of patients with early rheumatoid arthritis as detected by the company's EpiSwitch epigenetic biomarker platform...
08:00 , Jan 28, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: MicroRNA-186-5p (miR-186-5p); chemokine CXC motif ligand 13 (CXCL13); CXC chemokine receptor 5 (CXCR5)

Neurology INDICATION: Pain Mouse studies suggest promoting miR-186-5p expression or inhibiting CXCL13-CXCR5 signaling could help treat neuropathic pain. A mouse model of spinal nerve ligation-induced neuropathic pain had lower spinal cord levels of miR-186-5p, higher spinal cord...
07:00 , Oct 23, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Chronic lymphocytic leukemia (CLL) Lymphotoxin-a (LTa); lymphotoxin-b receptor (LTBR); chemokine CXC motif ligand 13 (CXCL13); CXC chemokine receptor...